Glaukos (GKOS) vs MiniMed Group (MMED)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Glaukos is the larger company by market cap ($9.51 billion vs $5.57 billion), about 1.7 times the size. On valuation, MiniMed Group trades at a lower forward P/E (31.1x vs 307.6x for Glaukos). MiniMed Group converts more of its revenue into profit, with a net margin of -10.7% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | MMED |
|---|---|---|
| Share price | $161.29 | $19.80 |
| Market cap | $9.51B | $5.57B |
| 1-day change | -6.32% | +3.61% |
| YTD return | +42.85% | — |
| 1-year return | +84.14% | — |
| 5-year return | +259.86% | — |
| Forward P/E | 307.61 | 31.07 |
| EPS (TTM) | $-3.26 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $3.10B |
| Revenue growth (YoY) | +32.33% | +14.25% |
| Net income (latest FY) | $-187.69M | $-333.00M |
| Gross margin | 55.72% | 54.16% |
| Operating margin | -39.33% | -6.13% |
| Net margin | -36.99% | -10.74% |
| 52-week high | $191.62 | $24.43 |
| 52-week low | $73.16 | $10.65 |
| Distance from 52-week high | -15.83% | -18.95% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.19% | +24.70% |
| Average volume | 831.71K | 2.48M |
| Shares outstanding | 58.98M | 281.35M |
| Employees | 1,094 | 8,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MiniMed Group is more profitable, keeping -10.7 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +14.25%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About MiniMed Group
MMED stock →MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.
Health Care · Medical/Dental Instruments · 8,000 employees
GKOS vs MMED FAQ
Which is bigger, Glaukos or MiniMed Group?
Glaukos (GKOS) is larger, with a market capitalization of $9.51B compared with $5.57B for MiniMed Group (MMED).
Are Glaukos and MiniMed Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.